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The purpose of this study was to determine if routine clinical assessment could reliably predict
in-hospital death in patients admitted with acute exacerbation of COPD (AECOPD).
Methods: In a case-crossover study the case records of AECOPD related deaths were reviewed.
Clinical and laboratory variables including performance status (WHO-PS) and a composite phys-
iological score (early warning score, EWS) at initial clinical assessment on final admission (FA)
and penultimate admission (PA) for AECOPD were compared.
Results: Sixty patients included in study, female 60%, mean age (SD) 75 (8.7) years. 98% had 2
admissions for AECOPD. On univariate analysis variables associated with death were: Charlson
score, WHO-PS, EWS, pH< 7.35, Urea and CRP. On multivariate analysis predictors of mortality
were: WHO-PS (OR 95% CI: 4.9 (1.06e22.61); pZ 0.04) and EWS (OR 95% CI: 3.39 (1.56e7.41);
pZ 0.002). ROC analysis of relationship between combined WHO-PS/EWS score and death gave
AUC 0.86; a total score 6 had sensitivity 78% and specificity 86.2% and on multivariate anal-
ysis OR (95% CI) for death was 19.3 (4.3e86.2); p< 0.0005.
Conclusion: In-hospital deaths from AECOPD may be predicted by assessment of WHO-PS and
EWS on admission to hospital.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Approximately 10% of the UK population over the age of 40
years suffers from chronic obstructive pulmonary disease
(COPD) and acute exacerbation of COPD (AECOPD) is the
single most common cause for emergency medical966 135 323, þ44 1429 522 283; f
dchestclinic.com (S.A. Murphy).
0 Elsevier Ltd. All rights reservedadmission to hospital.1,2 In the UK there are over 31,000
deaths due to COPD annually although the numbers may be
considerably higher.3 The inpatient mortality from AECOPD
is approximately 10e20% and the mortality within 12
months of an exacerbation is up to 49%.4
In stable COPD the risk of death increases with severity
of airflow obstruction, in the presence of hypoxaemia orax: þ44 1429 221 621.
.
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functional breathlessness, low body mass index and
frequent exacerbations.5e15 The BODE Index a composite
score of body mass index, airflow obstruction, dyspnoea
and exercise capacity, has been shown to be highly
predictive of mortality.16
In patients admitted to hospital with AECOPD there are
a number of poor prognostic indicators including severity of
hypoxia, presence of hypercapnia, pH< 7.35 and raised
CRP level.17e22 There is, however, no reliable predictor of
the terminal stage of the disease in individual patients. The
prognostic models used in the SUPPORT study, which were
based on the Acute Physiology and Chronic Health Evalua-
tion II, highlighted this difficulty.23
The prevalence of COPD is increasing, and by the year
2020 it is expected to become the third leading cause of
death in the world; therefore, there is increasingly a need
for tools that can reliably identify patients that are in the
terminal stages of the disease.24
As most COPD patients have multiple AECOPD related
hospital admissions prior to death an interval change in
clinical and laboratory variables, between the penultimate
and final (fatal) admission for AECOPD may help identify
the terminal stage of the disease. The purpose of this study
was to determine if routine clinical assessment that
includes a simple assessment of global performance and
a composite score of physiological impairment could
provide reliable predictors of death in hospital.
Methods
Study design and patient population
The study was a case-crossover design in which the study
subjects were patients that died in hospital from AECOPD,
and each subject served as his/her own control. We
compared clinical and laboratory variables when the
patients were admitted and died from AECOPD (case) with
their penultimate admission for AECOPD (control).
In-hospital deaths (2004e2007) from COPD were identi-
fied from the hospital admissions database. Patients were
included if the diagnosis of COPD had been confirmed
previously by spirometry, AECOPD was the reason for
hospital admission and clinical features satisfied accepted
definitions of AECOPD (2 of: increased dyspnoea,
increased sputum volume, increased sputum purulence),
and there was no other plausible cause of death.25,26
Data collected
On admission to hospital patients were assessed using
a standard proforma that included an evaluation of the
patients’ social circumstances (living aloneorwith carer) and
assessment of functional status from which we derived the
WHO-ECOG performance score (WHO-PS: 0 e Asymptomatic
and normal activity. 1 e Symptomatic but normal activity
other than physical work. 2 e Symptomatic; some limitation
of normal activity but up and about>50% of time during day;
self-caring. 3 e Symptomatic; in bed/chair> 50% of time
during day; requires some help with self-care. 4 e Chair/
Bedbound; cannot carry out any self-care).27The presence of co-morbidity was recorded and quanti-
fied according to the index of Charlson et al.28,29 The most
recent body mass index (BMI), drug therapy for COPD, use of
long-term oxygen therapy (LTOT), most recent FEV1, arterial
blood gas data (on admission and at 24 h), serum urea and
creatinine and C-reactive protein (CRP) were recorded.
Severity of COPD was graded according to the Global Initia-
tive on Obstructive Lung Disease (GOLD) staging classifica-
tion (2003).30 A composite score of physiological impairment
the Early Warning Score (EWS derived from: Heart Rate,
Systolic Blood Pressure, Respiratory rate, Temperature, CNS
score, and Urine output) was recorded on admission and at
intervals thereafter (Appendix 1).31,32 The highest value of
the EWS in each 24 h period was used in the analysis.
Analysis
Data was analysed using SPSS software (SPSS Inc., Chicago,
IL). Comparisons were made between the final (case) and
penultimate (control) admissions. Continuous data are
presented as means and standard deviation (SD) or as
medians and range unless otherwise stated. Continuous
variables were compared by matched pair t-test. Chi-
squared was used to compare categorical variables in
bivariate analysis. The relationship between variables and
death was examined by conditional logistic regression on
matched data. Variables that were significant on univariate
analysis (p< 0.05) were included in the multivariate anal-
ysis. The intervals between admission and from admission
to death was analysed by the KaplaneMeier method and
Cox proportional hazards regression analysis.
Results
Of 100 patients initially identified 60 satisfied the inclusion
criteria. A total of 97% had 2 admissions for AECOPD. The
median (IQ) number of previous admissions for AECOPD in the
12months prior to deathwas 1 (0e2) andmedian (IQ) interval
between penultimate (PA) and final admission (FA) was 14
(5e62) weeks. After controlling for social circumstances
(Lives alone: FA: 51.6%) and WHO-PS (FA) the interval
between admissions was shorter in patients receiving LTOT
(HR 2.61 (95% CI: 1.38e4.9) pZ 0.003; Fig. 1).
Clinical and laboratory variables on admission to hospital
are shown in Table 1. Sixty percent of patients were female;
themeanage at deathwas 75.3 (8.6) years.Most patients had
GOLD stage IV COPD (PA 89.6% v FA 90.0%) andmore than half
were receiving LTOT (PA 50% v FA 58%). Co-morbidity was
common particularly congestive cardiac failure and there
was a significant increase in Charlson co-morbidity index on
the final admission. Fifty percent of patients were described
as cachectic and/or had a BMI 20 kg/m2.
The frequency and number of days spent in hospital for
AECOPD related admissions in the previous 12 months were
greater on the final admission. Differences in maintenance
therapy for COPD between admissions included greater use
of inhaled corticosteroids (ICS) and tiotropium on the final
admission (ICS, PA 62% v FA 82%; p< 0.05; Tiotropium, PA
14% v FA 32%; p< 0.05). There were no differences in the
use of oral corticosteroid maintenance therapy (38%),
benzodiazepines (12%) or opiates (5%).
Figure 1 Interval between admissions to hospital for
AECOPD. (KaplaneMeier curve) for patients receiving long-
term oxygen therapy (LTOT; broken line) v no LTOT (solid line);
censored at 52 weeks. Cox proportional hazards analysis
included: social circumstances and WHO-PS as covariates.
Hazard Ratio for LTOT 2.61 (95% CI: 1.38e4.9) pZ 0.003.
Table 1 Clinical and laboratory variables on admission to hospit
admission; CR, creatinine; Aa-gradient, Alveolarearterial oxygen
M:F
Age, median (range) yrs
Admission rate, mean (SD)/yr
Days in hosp/yr, mean (SD)
FEV1, mean (SD) L
FEV1% predicted, mean (SD)
COPD severity by GOLD stage n (%)
Stage 2 (FEV1< 80% predicted)
Stage 3 (FEV1< 50% predicted)
Stage 4 (FEV1< 30% pred. or <50% pred.þ chronic respiratory fa
Additional co-morbidity n (%)
Congestive cardiac failure
Myocardial infarction
Stage 3 renal impairment
Malignancy
Charlson index, mean (SD)
WHO-PS, median (range)
Resp. rate, mean (SD)/min
GCS, median (range)
EWSo/a, median (range)
Hb, mean (SD) g/dl
Urea, mean (SD) mmol/l
CR, mean (SD) mmol/l
CRP, mean (SD) mg/l
Arterial pH, mean (SD)
Aa-gradient, mean (SD) KPa
Hypercapnia (PCO2> 6.0 KPa) n (%)
1670 S.A. Murphy et al.Significant differences between admissions were seen
for Charlson score, WHO-PS, EWS, Urea, CRP and arterial
pH. There were no differences in coma score and respira-
tory rate between admissions (other components of the
EWS were not included in the analysis). The degree of
hypoxia and frequency of hypercapnia were non-statisti-
cally greater on the final admission. Twice as many patients
required non-invasive ventilation on the final admission (PA
20% v FA 40%; p< 0.05). However, although the pH nor-
malised within 24 h in response to treatment the EWS
remained higher on the final compared to the penultimate
admission (Fig. 2).
Variables that were significant on univariate analysis
(Charlson score, WHO-PS, EWS on admission (EWSo/a), pH,
Urea and CRP) were included in a multivariate analysis of
factors associated with death. The pH and urea were con-
verted to dichotomous variables (pH< 7.35 and ure-
a> 7.0 mmol/l). In the multivariate analysis only WHO-PS
and EWSo/a were independently predictive of death from
AECOPD (Table 2).
Receiver operating characteristic (ROC) curve analysis
was used to define the best cut-off value for a combined
(WHO-PS plus EWSo/a) score in relation to death. A value of
0.80 for the area under the curve (AUC) was considered to
represent good discrimination. The sensitivity and speci-
ficity of the combined score was calculated at various
cut-off points. ROC curve analysis showed the combinedal. GCS, Glasgow coma score; EWSo/a, Early warning score on
gradient; and NS, p 0.05.
Penultimate
(nZ 58)
Final
(nZ 60)
p-Value
23:35 24:36 NS
75 (53e93) 76 (53e94) NS
1.45 (1.52) 1.97 (1.47) p< 0.05
14.2 (18) 20.6 (20) p< 0.001
0.72 (0.32) 0.74 (0.34) NS
33.4 (15.4)% 34 (16.8)% NS
2 (3.4%) 2 (3.3)
4 (7%) 4 (6.6%)
ilure) 52 (89.6%) 54 (90%)
33 (57%) 37 (61.6%) NS
17 (29.3%) 23 (38.3%) NS
5 (8.6%) 5 (8.3%)
6 (10.3)% 8 (13%)
2 (3.4%) 3 (5%)
4.90 (1.57) 5.14 (1.40) p< 0.01
2 (1e3) 3 (2e4) p< 0.001
23.3 (9.34) 24.8 (6.5) NS
15 (11e15) 15 (5e15) NS
2 (0e5) 4 (1e8) p< 0.001
13.52 (2.16) 13.19 (2.32) NS
8.9 (5.11) 12.3 (8.91) p< 0.05
106.6 (31.9) 129.2 (83.5) NS
33.0 (36.7) 86.1 (116.7) p< 0.05
7.34 (0.09) 7.28 (0.12) p< 0.05
5.49 (10.58) 12.31 (8.40) NS
39 (67.2%) 46 (76.60%) NS
Figure 2 Effect of treatment on pH and Early Warning Score
(EWS). Mean (95% CI); penultimate (PA) v final admission (FA):
EWS on admission (O/A) and after 24, and 48 h. *p< 0.05;
yp< 0.005; and {p< 0.001.
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death with an AUC of 0.86. A total score of 6 had a sensi-
tivity of 78% and specificity of 86.2% (Fig. 3). When included
in the regression as an ‘indicator variable’ (WHO-PS/
EWS 6) it was the only independent predictor of death
(OR 95% CI: 19.3 (4.3e86.2) p< 0.0005).
Time to death (in hospital) showed a bimodal distribution
withearly deaths (ED) occurring at amedian (range) of 2 (1e7)
days and latedeaths (LD)18 (8e52)days afteradmission.Early
death was associated with decompensated acidosis on
admission (pH< 7.35: ED 67.6% v LD 17%; p< 0.001). Fig. 4
shows survival after admission to hospital (covariates: Charl-
son score, WHO-PS, EWSo/a, Urea> 7.0, pH< 7.35, CRP).
Discussion
The mortality rate for patients admitted to hospital with
AECOPD is up to 49% within 2 years and rises with the
number of exacerbations.4,14 The prognosis for end-stage
COPD is comparable to that of inoperable non-small cell
lung cancer (NSCLC) but COPD patients receive substan-
tially less palliative and end-of-life care.33,34 One of the
reasons for this is the difficulty in determining the terminal
phase of the illness. Patients with end-stage COPD are
likely to experience several hospital admissions for AECOPD
before death and although a number of variables are
associated with poor prognosis in AECOPD these lack the
sensitivity or specificity required to identify patients dying
from the disease. It is, therefore, inevitable that in most
cases physicians continue active life-prolonging treatment,
however, seemingly futile.Table 2 Multivariate analysis of association between variables a
(p< 0.05) on univariate analysis were included. Odds Ratio (95%
Variable Odds
Step1 EWS(o/a) 3.45
Step 2 EWS(o/a) 3.39
WHO-PS 4.91
Adjusted Odds Ratios for covariates not included in model
Charlson score 1.62
pH< 7.35 0.95
Urea> 7.0 mmol/l 1.39
CRP 1.02Many of our findings are in keeping with observations
that have been previously reported by others. The risk of
death in patients with COPD increases with the severity of
airflow obstruction5; 90% of patients in this study had very
severe (GOLD stage 4) COPD. The frequency of AECOPD is
also an important prognostic factor.14,15 In the study by
Soler-Catalun˜a et al. patients with frequent exacerbations
had a risk of death 4.3 times greater (95% CI: 2.62e7.02)
than patients not requiring hospital admission. All but two
of our patients had at least one previous admission for
AECOPD and there was a significant increase in the
annualised rate of admission for AECOPD in the final 12
months of life. However, the number and interval between
exacerbations varied widely and was greater than 12
months in some patients. The shorter interval between
admissions for patients receiving long-term oxygen therapy
(LTOT) is in keeping with previous studies that found LTOT
to be a marker for readmission.35 The increased frequency
of prescriptions for inhaled corticosteroids and tiotropium
on the final admission probably reflects the increased
severity of the disease.36
BMI has been shown to be an independent predictor of
long-term prognosis in COPD.12,13 Landbo et al. observed
a relative risk of death of 7.1 (range: 2.97e17.05) in
patients with severe COPD and a BMI< 20 kg/m2 compared
with obese subjects. However, in the present study BMI did
not differ between the two admissions. Indeed although
50% of our patients were described as cachectic or had
a BMI 20 kg; the average BMI (recorded) was within the
normal range.
The importance of co-morbidities in patients with COPD
is well recognised, particularly cardiovascular and other
smoking related diseases.37 In a retrospective study of
71,130 patients admitted to hospital with AECOPD patients
with a Charlson score of 5 were more than five times as
likely to die in hospital compared with patients without co-
morbidities.38 However, in the prospective study by Groe-
newegen et al. of 171 patients hospitalised for ACOPD more
than two-thirds had at least one co-morbid illness but the
Charlson score was not independently associated with an
increased risk of death.18 Similarly in the present study co-
morbidity was considerable but although there was
a significant increase in the Charlson score between
admissions it was not an independent predictor of death in
our patients with end-stage disease.
Breathlessness and exercise capacity have both been
found to be better predictors of mortality than FEV1 in
patients with COPD.9e11 In the study by Nishimura a score ofnd death. Forward conditional regression; variables significant
CI) for 1 unit increase in value of variable.
Ratio 95% C.I. p-Value
1.59e7.50 0.002
1.56e7.41 0.002
1.06e22.61 0.041
0.75e3.51 0.196
0.13e6.49 0.740
0.18e10.70 0.684
0.99e1.04 0.064
Figure 3 ROC curve analysis of combined WHO/EWS(o/a)
score and death. AUC 0.86. The best cut-off value was
combined WHO-PS/EWSo/a scoreZ 6 (sensitivity of 78% and
specificity of 86.2%).
1672 S.A. Murphy et al.5 on the modified MRC-dyspnoea score was highly predic-
tive of long-term mortality with a relative risk compared to
grade 2 dyspnoea of 61.3 (95% CI: 13.2e285.4).9 Oga et al.
found that exercise capacity measured by VO2max was the
best predictor of mortality.10 Pinto-Plata et al. observed
close correlation between six-minute walk distance (6MWD)
and survival; those with a 6MWD< 100 m had a 1-year
mortality> 60%.11 Combining prognostic variables that
reflect the systemic manifestations and functional impair-
ment in COPD to create a severity score, the BODE index,
has greater predictive power for mortality than individual
variables.16 However, in patients with very advancedFigure 4 KaplaneMeier Survival Curve on final admission to
hospital. Decompensated acidosis (Broken line) v No acidosis
(Solid line). Cox proportional hazards analysis included Charl-
son score, WHO-PS, EWSo/a, Urea> 7.0 mmol/l, CRP as cova-
riates. Hazard Ratio for acidosis: 0.207 (95% CI: 0.076e0.566)
pZ 0.002.disease it has limitations; a BODE score in the upper quar-
tile is associated with a 12 month mortality of only 5% and
is, therefore, of limited utility in identifying patients in the
terminal stages of the disease.
Measurement of performance status is integral to the
assessment of patients with COPD. The St. George’s (SGRQ)
and the Chronic Respiratory Disease Questionnaire (CRQ)
are invaluable in studies of interventions; however, they
are impractical for routine clinical use.39,40 The WHO-PS
provides a simple and reliable measure of global perfor-
mance that most physicians are familiar with. We are
unaware of any previous reports of the WHO-PS as an
instrument for assessing this group or patients. However, in
the UK National COPD Audit (2003) a very similar 5-point
assessment of performance status was a better predictor of
mortality (2% in the best category compared with 38% in the
most severe; bed or chair bound) than the more respiratory
specific factors.41 This concurs with the finding of this study
in which there is a threshold for mortality between a WHO-
PS score of 2 (self-caring and up and about 50% of the time)
and 3 (needing help with self-care and in bed/chair> 50%
of the time during the day).
The Early Warning Score (EWS) is a tool for bedside eval-
uation based on six physiological parameters: pulse rate,
systolic blood pressure, respiratory rate, temperature, CNS
score and urine output (Appendix 1). The EWS, originally
developed for surgical patients, has been validated for use in
medical patients in whom a score> 3 on admission to
hospital was associated with a mortality of about 25%.31,32
The finding of a highly significant association between EWS
and death in the present study is indicative of systemic
physiological disturbance in end-stage COPD. This is reflec-
ted in the more severe biochemical derangement including
lower pH and raised blood urea concentration.
The relationship between in-hospital mortality due to
COPD and decompensated acidosis is well established.19,21 In
the UK national audit of COPD admissions (1997) risk of death
was related to severity of acidosis (Relative Risk (95%CI) for
pH 7.26e7.34, RR 1.9 (1.3e2.83); pH< 7.26, RR 3.8
(2.7e5.4)).19 In the present study more patients were
acidotic on the final admission and acidosis was associated
with a shorter interval to death indicating that these patients
are the most acutely unwell. However, in the terminally ill
COPDpatient pH improvedwith treatmentwhilst the EWSdid
not unlike on the penultimate admission. Furthermore
respiratory specific variables were not associatedwith death
implying that in patients dying from COPD there is more
generalised systemic disturbance. This is supported by the
finding of an increased urea on the final admission. An asso-
ciation between uraemia and death from COPD has been
reported previously.21 Jeffrey et al. also reported a rela-
tionship between death and systolic hypotension and inti-
mated that these findings reflected the severity of systemic
disturbance associated with an exacerbation. The EWS,
based upon routine clinical observations, provides a useful
measure of that systemic disturbance.
Systemic manifestations of COPD may be related to
systemic inflammation which is increasingly recognised as
a risk factor for complications of COPD42; patients with
COPD have raised levels of CRP and other markers of
systemic inflammation compared with healthy controls.
The CRP level increases during AECOPD and has been
Predicting end-of life in patients with an exacerbation of COPD 1673related to ‘Anthonisen exacerbation type’ with the highest
levels in type 1 exacerbation.43 In the present study CRP
levels in both groups were in the range seen in type 1
exacerbations reported by Stolz et al. The level of CRP has
also been related to mortality; Ruiz-Gonza´lez et al.
observed an increased risk of adverse outcome including
death in patients with a CRP> 50 mg/l.22 We also found
higher CRP levels in relation to death but the frequency of
CRP> 50 mg/l did not differ significantly between admis-
sions (PA 17.8% v FA 36%; pZ 0.09).
Previous studies relating to mortality in COPD have been
in patients with a wide range of severity of the condition
and do not address the question of short-term prognosis.
The benefit of the case-crossover design employed in this
study is that it has enabled us to specifically investigate
clinical changes over the final weeks of life in patients with
end-stage COPD. We accept that the retrospective nature
of the study has inherent shortcomings including selection
bias. However, the differences observed over a short period
(about 3e4 months in most cases) within a homogeneous
cohort of patients are likely to be smaller than would have
been the case in a broader range of patients.
The purpose of this study was to determine if routine
clinical assessment of patientswith severe COPD admitted to
hospital could identify the “tipping point” in the disease
thereby facilitating the transition from life-prolonging
treatment to end-of-life care. Our observations suggest that
a combination of assessment of global performance status
and a measure of acute systemic physiological impairment
may enable this. In this study combining theWHO-PS andEWS
scores gave an objective measurement that was highly
specific for death in patientswith very severeCOPDadmitted
to hospital with an acute exacerbation. The EWS is used
routinely inmost hospitals in theUK and theWHO-PS could be
readily incorporated into clinical assessment proformas. The
potential utility of this is clear but prospective studies are
required to confirm our findings.
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